Paper Details

  1. Home
  2. Paper Details

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.

Author: AbrahamP, ChanC K, LinS G, McCannelC A, NuthiA S D, SarrafD

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This prospective study of 136 patients with vascularized pigment epithelial detachment (vPED) due to age-related macular degeneration compared the outcomes of 0.5 vs 2.0 mg intravitreal ranibizumab injections (RI). Both doses yielded similar visual and anatomical outcomes at the end of the study; however, the higher dose yielded more rapid reductions and more complete resolution of the PED, although there was possible increased tendency for an RPE tear with the higher dose.
Paper Details　
Original Abstract of the Article :
SUMMARY STATEMENT: Intravitreal high dose (2 mg) ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated retinal pigment epithelial detachment in eyes with exudative age-related macular degeneration, although it may possibly correlate with RPE tears in certain...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289828/

データ提供：米国国立医学図書館（NLM）

High-Dose Ranibizumab: A Speedy Remedy for Vascularized Pigment Epithelial Detachments?

Age-related macular degeneration (AMD) is a leading cause of vision loss. This research investigates the efficacy of intravitreal high-dose (2.0 mg) ranibizumab injections (RI) in treating vascularized pigment epithelial detachment (vPED) associated with AMD. The study utilizes a prospective design to compare the outcomes of high-dose ranibizumab with standard-dose ranibizumab.

High-Dose Therapy: A Faster Route to Recovery?

The study findings suggest that high-dose ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated vPED. However, it also notes a possible increased risk of RPE tears with the higher dose. The researchers conclude that while both doses achieve similar outcomes in the long run, the higher dose may offer a faster path to improvement.

Navigating Treatment Options for AMD: A Careful Balance

This research highlights the complexity of AMD treatment. The study findings emphasize the need for careful consideration of individual patient factors, including the potential risks and benefits of different treatment approaches. Patients with AMD should discuss treatment options with their ophthalmologist to determine the most appropriate course of action.

Dr. Camel's Conclusion

Treating AMD is like navigating a challenging dune field—finding the right path requires careful planning. This research provides valuable insights into the potential benefits and risks of high-dose ranibizumab, emphasizing the need for a tailored approach to AMD treatment.

Date :
  1. Date Completed 2015-07-22
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25277305

DOI: Digital Object Identifier

PMC4289828

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.